Navigation Links
Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business

PRINCETON, N.J., Oct. 6 /PRNewswire/ -- Laureate Pharma, Inc., a full-service contract development and manufacturing organization today announced that it has secured $20 million in debt and equity financing to enhance and grow its business.  

Building on nearly 30 years of experience in the development and supply of protein drug products produced from mammalian cell culture, Laureate Pharma will be able to better serve its clients by accelerating their timelines from development through production.

"Today marks a significant milestone in our efforts to relaunch Laureate Pharma," said Michael A. Griffith, Chief Executive Officer.  "Our strategically planned improvements coupled with our solid financial footing will position us for exceptional growth."

Mr. Griffith continued, "As we transform Laureate, care will be taken to maintain continuity of client services.  Quality Assurance will oversee investment activities to ensure our offerings comply with the strict demands of global regulatory agencies."

The new funds will be used to drive five investment initiatives over a three-year period and will provide a more robust portfolio of services to better serve customers' needs and include:

  • Upgrading  aseptic fill capabilities through the construction of a new segregated fill suite and the installation of a new fully-automated fill line incorporating vial washing, depyrogenation, filling, and capping.  All product contact pathways of the new line will be single-use disposable. Commissioning is planned for early 2012.
  • Upgrading protein production services to increase bioreactor (2000L) and purification (10L chromatography skid) capacity, new gowning rooms, renovated purification suites and additional support utilities.
  • Launching a contract analytical testing business to serve a broader client base including clients who do not require other Laureate services.  Laureate will enhance sample management procedures, upgrade and add new instrumentation to offer a full range of testing required to characterize protein products.  
  • Expanding mammalian cell line creation services; in 2011, Laureate will offer access to a variety of protein expression systems that can be selected based on the specific characteristics and requirements of the protein product.   Additionally, the Company plans to add cGMP cell banking services.
  • Adopting new quality systems technologies including new systems to manage inventory, deviations, and calibration and validation.  In addition, the Company will acquire a new software solution that will enable it to assemble documentation for clients in an eCTD format.  Finally, Laureate will expand its regulatory affairs unit to assist clients in the preparation of data summaries, batch reports and regulatory submissions.

Laureate Pharma has added 10 new jobs since bringing on a new CEO and a new Vice President of Business Development and plans to fill 50 more positions when working at capacity.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical contract development and manufacturing organization.  Laureate's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins.  In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support.  Laureate has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.

About Saints Capital, LLC

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Pharma, at (609) 919-3367, or or visit or Jennifer Vollaro at Integrated Marketing Services at (609) 683.9055 ext. 247, or

SOURCE Laureate Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
2. Thomson Reuters Predicts Nobel Laureates
3. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
4. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
5. AstraZeneca and the Sacramento County Pharmacy Provide Free Medicines to Eligible California Patients
6. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
7. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
8. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
9. Reportlinker Adds US Pharmaceutical Market Overview - Healthcare reform, economic pressures and the patent cliff set to impact Pharma
10. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
11. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
Post Your Comments:
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
(Date:11/24/2015)... Va. , Nov. 24, 2015  DILON Diagnostics ... have signed an agreement for DILON to distribute GE,s ... across the globe. The signing of this distribution agreement will ... NM750b Molecular Breast Imaging system and is considered an ... provide better healthcare solutions for clinicians and their patients. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also known ... people who find their cholesterol levels and weight are creeping up are more likely ... don’t have any of the other symptoms. , Thyroid hormone plays a major role ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis ... Care Plan software creates an agreement between the practice owner and the patient ... scheduling, monitoring, notification, and projections. Click here to learn more. ...
(Date:11/24/2015)... ... , ... Charitable giving is at its peak during the holidays. In ... of the year totalling over $358 billion in 2014. With more than 1.5 ... those individuals who want to “give back” during the holidays. , “With so many ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
Breaking Medicine News(10 mins):